|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||116.89 - 120.06|
|52 Week Range||112.39 - 131.56|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.20%|
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
Waiting for a bear market may seem like waiting for Godot—it’s been 3,297 days since the last bear market ended on March 9, 2009. Ramsey points out that foreign stocks in the MSCI EAFE index have been lagging the U.S. market this year, and they now trade at 26% discount to the MSCI USA index based on “normalized” price/earnings ratios (which smooth out the volatility in earnings over multi-year periods). The EAFE traded at the same discount in May 2010—the start of an “epic phase of underperformance” compared with the U.S. market, he says in a recent blog post.
The cornerstone of asset allocation has been that bonds offer a buffer to stocks when they tumble. Two quant strategists took a closer look at where investors may want to seek cover: Pavilion Global Market’s quantitative macro analyst Antoine Naly says bonds have not always acted as a buffer for stock meltdowns. Going back to the 19 century, Naly says correlations between bond and equity returns sometimes turn positive—and for long periods of time too, when inflation rates were rising like in the 1970s. While Naly says we are a long ways off from those rates, there is evidence to suggest we are moving toward a more inflationary period, at least on a cyclical basis.
Abbott Laboratories (ABT) released its 4Q17 and fiscal 2017 earnings results on January 24, 2018. Abbott seems quite confident about its strong product pipeline and recent product launches. In 2017, Abbott Laboratories launched a number of innovative products and expanded across geographies and business segments.
Last week I highlighted the Top 10 Value Stocks In The S&P 500 noting that “value will have its day in the sun” in 2018. But what are the S&P 500’s most expensive stocks?
Large-cap and growth stocks continue to beat small-caps and value, even though everyone thought the tide would turn this year.
A potential problem for value investors that favor index funds in the months ahead: Value indexes are loaded to the gills with competing holdings that are likely to offset each other.
Growth stocks have surged this year in the ongoing post-election rally, but more recently, the value style and related exchange traded funds are beginning to pull ahead. Year-to-date, the iShares Russell ...
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.
Dividend strategies have drawn increasing interest from investors around the world as central banks have pursued both quantitative and qualitative easy monetary policies, keeping interest rates at what have been exceptionally low levels since 2008. But this preference isn’t entirely new; it has long been known many investors have a preference for cash dividends. From the perspective of classical financial theory, this behavior is an anomaly.
On August 22, 2017, Baxter International entered into a collaboration with ASPEN (American Society for Parenteral and Enteral Nutrition) and launched SmartPN.
Baxter International (BAX) released its 2Q17 earnings results on July 26, beating the analysts' estimates for both revenues and earnings per share.